A retrospective study evaluating efficacy and safety of low dose Apatinib combined with original targeted drugs in treating advanced non-small-cell lung cancer after first-generation EGFR-TKIs treatment failure
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer